<DOC>
	<DOC>NCT00811018</DOC>
	<brief_summary>This is a multi-center, open-label study of sitaxsentan sodium 100 mg taken orally once daily by subjects with PAH until sitaxsentan, in a particular country or region, is commercially available for the treatment of PAH or the study is closed.</brief_summary>
	<brief_title>A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension</brief_title>
	<detailed_description>Open-label extension</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Sitaxsentan</mesh_term>
	<criteria>Diagnosis of Pulmonary Arterial Hypertension (PAH) confirmed by cardiac catheterization. Current diagnosis of WHO group 1 PAH with functional class 2, 3, or 4 symptoms. Has portal hypertension or chronic liver disease. Has history of left sided heart disease or significant cardiac disease.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Open-label study</keyword>
</DOC>